A real‐world data of Immune checkpoint inhibitors in solid tumors from India

BACKGROUND: Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Noronha, Vanita, Abraham, George, Patil, Vijay, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Jain, Srushti, Talreja, Vikas T, Kapoor, Akhil, Kumar Singh, Gunjesh, Khaddar, Satvik, Gupta, Kushal, Rathinasamy, Narmadha, Srinivas, Sujay, Agrawal, Amit, Ventrapati, Pradeep, Prabhash, Kumar
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940210/
https://ncbi.nlm.nih.gov/pubmed/33591635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3617
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars